AMYRA Biotech
Pre-clinicalAMYRA Biotech: Developing innovative enzyme therapy (BBEST) for celiac disease and gluten sensitivity. Swiss biotech improving digestive enzyme function.
Founded
2018
Focus
Biologics
About
AMYRA Biotech: Developing innovative enzyme therapy (BBEST) for celiac disease and gluten sensitivity. Swiss biotech improving digestive enzyme function.
Funding History
1Total raised: $2.5M
Seed$2.5MUndisclosedJun 15, 2021
Company Info
TypePrivate
Founded2018
LocationZug, Switzerland
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
3Brain
Pre-clinical · Zug
Baxiva
Pre-clinical · Zug
AC Bioscience
Pre-clinical · Lausanne
Abrinca Genomics
Pre-clinical · Zurich
AdipoGen
Pre-clinical · Liestal
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile